Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas

Carlton D. Donald, Carrie Q. Sun, So Dug Lim, Jill Macoska, Cynthia Cohen, Mahul Amin, Andrew N. Young, Tomas A. Ganz, Fray F. Marshall, John A. Petros

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

In a previous large-scale gene expression profiling study of renal epithelial neoplasms, human β-defensin-1 (DEFB1) was found to be significantly down-regulated in conventional clear cell (renal) carcinoma. We have now completed an expanded expression analysis of this gene. We performed immunohistochemical analysis for the DEFB1 protein in clinical specimens of both renal cell carcinoma and prostate cancer. In a subset of prostate cancers, we performed laser capture microdissection and RT-PCR to correlate mRNA levels with protein levels. Overall, 82% of prostate cancers exhibit either complete loss of protein expression or only minimal expression, whereas the adjacent benign epithelium retained expression in all cases. Similarly, 90% of renal cell carcinomas show cancer-specific loss of DEFB1 protein. In the prostate cancer subset analysis, mRNA levels correlate with protein levels. We have thus demonstrated the cancer-specific down-regulation of DEFB1 in a large sample of prostatic and renal carcinomas and validated one of the key findings of previous cancer gene profiling studies of prostatic and renal neoplasia.

Original languageEnglish (US)
Pages (from-to)501-505
Number of pages5
JournalLaboratory Investigation
Volume83
Issue number4
DOIs
StatePublished - Apr 1 2003
Externally publishedYes

Fingerprint

Defensins
Renal Cell Carcinoma
Prostatic Neoplasms
Carcinoma
Kidney
Neoplasms
Proteins
Laser Capture Microdissection
Messenger RNA
Glandular and Epithelial Neoplasms
Kidney Neoplasms
Neoplasm Genes
Gene Expression Profiling
Down-Regulation
Epithelium
Gene Expression
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Molecular Biology
  • Cell Biology

Cite this

Donald, C. D., Sun, C. Q., Lim, S. D., Macoska, J., Cohen, C., Amin, M., ... Petros, J. A. (2003). Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas. Laboratory Investigation, 83(4), 501-505. https://doi.org/10.1097/01.LAB.0000063929.61760.F6

Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas. / Donald, Carlton D.; Sun, Carrie Q.; Lim, So Dug; Macoska, Jill; Cohen, Cynthia; Amin, Mahul; Young, Andrew N.; Ganz, Tomas A.; Marshall, Fray F.; Petros, John A.

In: Laboratory Investigation, Vol. 83, No. 4, 01.04.2003, p. 501-505.

Research output: Contribution to journalArticle

Donald, CD, Sun, CQ, Lim, SD, Macoska, J, Cohen, C, Amin, M, Young, AN, Ganz, TA, Marshall, FF & Petros, JA 2003, 'Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas', Laboratory Investigation, vol. 83, no. 4, pp. 501-505. https://doi.org/10.1097/01.LAB.0000063929.61760.F6
Donald, Carlton D. ; Sun, Carrie Q. ; Lim, So Dug ; Macoska, Jill ; Cohen, Cynthia ; Amin, Mahul ; Young, Andrew N. ; Ganz, Tomas A. ; Marshall, Fray F. ; Petros, John A. / Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas. In: Laboratory Investigation. 2003 ; Vol. 83, No. 4. pp. 501-505.
@article{a5daffe69feb467c9b20413f89928df0,
title = "Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas",
abstract = "In a previous large-scale gene expression profiling study of renal epithelial neoplasms, human β-defensin-1 (DEFB1) was found to be significantly down-regulated in conventional clear cell (renal) carcinoma. We have now completed an expanded expression analysis of this gene. We performed immunohistochemical analysis for the DEFB1 protein in clinical specimens of both renal cell carcinoma and prostate cancer. In a subset of prostate cancers, we performed laser capture microdissection and RT-PCR to correlate mRNA levels with protein levels. Overall, 82{\%} of prostate cancers exhibit either complete loss of protein expression or only minimal expression, whereas the adjacent benign epithelium retained expression in all cases. Similarly, 90{\%} of renal cell carcinomas show cancer-specific loss of DEFB1 protein. In the prostate cancer subset analysis, mRNA levels correlate with protein levels. We have thus demonstrated the cancer-specific down-regulation of DEFB1 in a large sample of prostatic and renal carcinomas and validated one of the key findings of previous cancer gene profiling studies of prostatic and renal neoplasia.",
author = "Donald, {Carlton D.} and Sun, {Carrie Q.} and Lim, {So Dug} and Jill Macoska and Cynthia Cohen and Mahul Amin and Young, {Andrew N.} and Ganz, {Tomas A.} and Marshall, {Fray F.} and Petros, {John A.}",
year = "2003",
month = "4",
day = "1",
doi = "10.1097/01.LAB.0000063929.61760.F6",
language = "English (US)",
volume = "83",
pages = "501--505",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Cancer-specific loss of β-defensin 1 in renal and prostatic carcinomas

AU - Donald, Carlton D.

AU - Sun, Carrie Q.

AU - Lim, So Dug

AU - Macoska, Jill

AU - Cohen, Cynthia

AU - Amin, Mahul

AU - Young, Andrew N.

AU - Ganz, Tomas A.

AU - Marshall, Fray F.

AU - Petros, John A.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - In a previous large-scale gene expression profiling study of renal epithelial neoplasms, human β-defensin-1 (DEFB1) was found to be significantly down-regulated in conventional clear cell (renal) carcinoma. We have now completed an expanded expression analysis of this gene. We performed immunohistochemical analysis for the DEFB1 protein in clinical specimens of both renal cell carcinoma and prostate cancer. In a subset of prostate cancers, we performed laser capture microdissection and RT-PCR to correlate mRNA levels with protein levels. Overall, 82% of prostate cancers exhibit either complete loss of protein expression or only minimal expression, whereas the adjacent benign epithelium retained expression in all cases. Similarly, 90% of renal cell carcinomas show cancer-specific loss of DEFB1 protein. In the prostate cancer subset analysis, mRNA levels correlate with protein levels. We have thus demonstrated the cancer-specific down-regulation of DEFB1 in a large sample of prostatic and renal carcinomas and validated one of the key findings of previous cancer gene profiling studies of prostatic and renal neoplasia.

AB - In a previous large-scale gene expression profiling study of renal epithelial neoplasms, human β-defensin-1 (DEFB1) was found to be significantly down-regulated in conventional clear cell (renal) carcinoma. We have now completed an expanded expression analysis of this gene. We performed immunohistochemical analysis for the DEFB1 protein in clinical specimens of both renal cell carcinoma and prostate cancer. In a subset of prostate cancers, we performed laser capture microdissection and RT-PCR to correlate mRNA levels with protein levels. Overall, 82% of prostate cancers exhibit either complete loss of protein expression or only minimal expression, whereas the adjacent benign epithelium retained expression in all cases. Similarly, 90% of renal cell carcinomas show cancer-specific loss of DEFB1 protein. In the prostate cancer subset analysis, mRNA levels correlate with protein levels. We have thus demonstrated the cancer-specific down-regulation of DEFB1 in a large sample of prostatic and renal carcinomas and validated one of the key findings of previous cancer gene profiling studies of prostatic and renal neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=0037391009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037391009&partnerID=8YFLogxK

U2 - 10.1097/01.LAB.0000063929.61760.F6

DO - 10.1097/01.LAB.0000063929.61760.F6

M3 - Article

VL - 83

SP - 501

EP - 505

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 4

ER -